Epilepsy neurosurgery is added to the abnormal reaction of a formulation containing Empagliflozin, an SGLT-2 inhibitor used to treat type 2 diabetes. The Ministry of Food and Drug Safety announced a change in permits based on the results of a review of safety information on Empagliflozin-containing drugs by EC and EMA. The drugs that announce the change of permits are 104 items such as Jardiance, an Empagliflozin-based drug of Beringer Ingelheim Korea, 106 items such as Jardiance Duo, an Empagliflozin and Metformin complex, and SGLT-2, an Empagliflozin and Linaglipin complex. As a result of a review by the Ministry of Food and Drug Safety, "interstitial neurosurgery" is added to the abnormal response term for both Emp